These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 28644737

  • 1. Circulatory CNP Rescues Craniofacial Hypoplasia in Achondroplasia.
    Yamanaka S, Nakao K, Koyama N, Isobe Y, Ueda Y, Kanai Y, Kondo E, Fujii T, Miura M, Yasoda A, Nakao K, Bessho K.
    J Dent Res; 2017 Dec; 96(13):1526-1534. PubMed ID: 28644737
    [Abstract] [Full Text] [Related]

  • 2. Circulatory C-type natriuretic peptide reduces mucopolysaccharidosis-associated craniofacial hypoplasia in vivo.
    Kashiwagi M, Nakao K, Yamanaka S, Yamauchi I, Yamashita T, Fujii T, Ueda Y, Kawai MY, Watanabe T, Fukuhara S, Bessho K.
    PLoS One; 2022 Dec; 17(11):e0277140. PubMed ID: 36355797
    [Abstract] [Full Text] [Related]

  • 3. Maternal administration of meclozine for the treatment of foramen magnum stenosis in transgenic mice with achondroplasia.
    Matsushita M, Mishima K, Esaki R, Ishiguro N, Ohno K, Kitoh H.
    J Neurosurg Pediatr; 2017 Jan; 19(1):91-95. PubMed ID: 27767902
    [Abstract] [Full Text] [Related]

  • 4. The effects of C-type natriuretic peptide on craniofacial skeletogenesis.
    Nakao K, Okubo Y, Yasoda A, Koyama N, Osawa K, Isobe Y, Kondo E, Fujii T, Miura M, Nakao K, Bessho K.
    J Dent Res; 2013 Jan; 92(1):58-64. PubMed ID: 23114031
    [Abstract] [Full Text] [Related]

  • 5. Foramen magnum stenosis and midface hypoplasia in C-type natriuretic peptide-deficient rats and restoration by the administration of human C-type natriuretic peptide with 53 amino acids.
    Yotsumoto T, Morozumi N, Furuya M, Fujii T, Hirota K, Ueda Y, Nakao K, Yamanaka S, Yoshikiyo K, Yoshida S, Nishimura T, Abe Y, Jindo T, Ogasawara H, Yasoda A.
    PLoS One; 2019 Jan; 14(5):e0216340. PubMed ID: 31120905
    [Abstract] [Full Text] [Related]

  • 6. Effect of C-type natriuretic peptide on craniofacial skeletogenesis in mice during the pubertal growth spurt.
    Kashiwagi M, Nakao K, Yamanaka S, Yamauchi I, Yamashita T, Fujii T, Ueda Y, Kawai MY, Watanabe T, Fukuhara S, Bessho K.
    Arch Oral Biol; 2022 Jul; 139():105433. PubMed ID: 35525017
    [Abstract] [Full Text] [Related]

  • 7. Chronically elevated plasma C-type natriuretic peptide level stimulates skeletal growth in transgenic mice.
    Kake T, Kitamura H, Adachi Y, Yoshioka T, Watanabe T, Matsushita H, Fujii T, Kondo E, Tachibe T, Kawase Y, Jishage K, Yasoda A, Mukoyama M, Nakao K.
    Am J Physiol Endocrinol Metab; 2009 Dec; 297(6):E1339-48. PubMed ID: 19808910
    [Abstract] [Full Text] [Related]

  • 8. Circulating C-type natriuretic peptide (CNP) rescues chondrodysplastic CNP knockout mice from their impaired skeletal growth and early death.
    Fujii T, Komatsu Y, Yasoda A, Kondo E, Yoshioka T, Nambu T, Kanamoto N, Miura M, Tamura N, Arai H, Mukoyama M, Nakao K.
    Endocrinology; 2010 Sep; 151(9):4381-8. PubMed ID: 20610569
    [Abstract] [Full Text] [Related]

  • 9. FGFR3 mutation causes abnormal membranous ossification in achondroplasia.
    Di Rocco F, Biosse Duplan M, Heuzé Y, Kaci N, Komla-Ebri D, Munnich A, Mugniery E, Benoist-Lasselin C, Legeai-Mallet L.
    Hum Mol Genet; 2014 Jun 01; 23(11):2914-25. PubMed ID: 24419316
    [Abstract] [Full Text] [Related]

  • 10. C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia.
    Legeai-Mallet L.
    Endocr Dev; 2016 Jun 01; 30():98-105. PubMed ID: 26684019
    [Abstract] [Full Text] [Related]

  • 11. FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.
    Matsushita T, Wilcox WR, Chan YY, Kawanami A, Bükülmez H, Balmes G, Krejci P, Mekikian PB, Otani K, Yamaura I, Warman ML, Givol D, Murakami S.
    Hum Mol Genet; 2009 Jan 15; 18(2):227-40. PubMed ID: 18923003
    [Abstract] [Full Text] [Related]

  • 12. Longitudinal Imaging of the Skull Base Synchondroses Demonstrate Prevention of a Premature Ossification After Recifercept Treatment in Mouse Model of Achondroplasia.
    Rignol G, Garcia S, Authier F, Smith K, Tosello L, Marsault R, Dellugat P, Goncalves D, Brouillard M, Stavenhagen J, Santarelli L, Czech C, Gouze E.
    JBMR Plus; 2022 Feb 15; 6(2):e10568. PubMed ID: 35229060
    [Abstract] [Full Text] [Related]

  • 13. Promising horizons in achondroplasia along with the development of new drugs.
    Ozono K, Kubota T, Michigami T.
    Endocr J; 2024 Jul 12; 71(7):643-650. PubMed ID: 38569854
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
    Lorget F, Kaci N, Peng J, Benoist-Lasselin C, Mugniery E, Oppeneer T, Wendt DJ, Bell SM, Bullens S, Bunting S, Tsuruda LS, O'Neill CA, Di Rocco F, Munnich A, Legeai-Mallet L.
    Am J Hum Genet; 2012 Dec 07; 91(6):1108-14. PubMed ID: 23200862
    [Abstract] [Full Text] [Related]

  • 15. Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.
    Pannier S, Mugniery E, Jonquoy A, Benoist-Lasselin C, Odent T, Jais JP, Munnich A, Legeai-Mallet L.
    Bone; 2010 Nov 07; 47(5):905-15. PubMed ID: 20673820
    [Abstract] [Full Text] [Related]

  • 16. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway.
    Yasoda A, Komatsu Y, Chusho H, Miyazawa T, Ozasa A, Miura M, Kurihara T, Rogi T, Tanaka S, Suda M, Tamura N, Ogawa Y, Nakao K.
    Nat Med; 2004 Jan 07; 10(1):80-6. PubMed ID: 14702637
    [Abstract] [Full Text] [Related]

  • 17. [Genetic basis for skeletal disease. CNP therapy for achondroplasia].
    Yasoda A, Nakao K.
    Clin Calcium; 2010 Aug 07; 20(8):1212-8. PubMed ID: 20675932
    [Abstract] [Full Text] [Related]

  • 18. Meckel's and condylar cartilages anomalies in achondroplasia result in defective development and growth of the mandible.
    Biosse Duplan M, Komla-Ebri D, Heuzé Y, Estibals V, Gaudas E, Kaci N, Benoist-Lasselin C, Zerah M, Kramer I, Kneissel M, Porta DG, Di Rocco F, Legeai-Mallet L.
    Hum Mol Genet; 2016 Jul 15; 25(14):2997-3010. PubMed ID: 27260401
    [Abstract] [Full Text] [Related]

  • 19. Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism.
    Wendt DJ, Dvorak-Ewell M, Bullens S, Lorget F, Bell SM, Peng J, Castillo S, Aoyagi-Scharber M, O'Neill CA, Krejci P, Wilcox WR, Rimoin DL, Bunting S.
    J Pharmacol Exp Ther; 2015 Apr 15; 353(1):132-49. PubMed ID: 25650377
    [Abstract] [Full Text] [Related]

  • 20. Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia.
    Lee YC, Song IW, Pai YJ, Chen SD, Chen YT.
    Sci Rep; 2017 Feb 23; 7():43220. PubMed ID: 28230213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.